45,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
23 °P sammeln
  • Broschiertes Buch

The discovery and development of novel small molecule drugs to fight cancer is a challenging task. This book shows the whole path, from the hit identification and hit-to-lead process to the preclinical studies, required to validate therapeutic targets and to develop novel anticancer treatments that could potentially reach the clinic. Here, two new series of compounds are described: a family of antiangiogenic compounds, and a series of ICMT inhibitors that block Ras activity. These are two innovative examples of some of the most recent advances in the Medicinal Chemistry field, in the search…mehr

Produktbeschreibung
The discovery and development of novel small molecule drugs to fight cancer is a challenging task. This book shows the whole path, from the hit identification and hit-to-lead process to the preclinical studies, required to validate therapeutic targets and to develop novel anticancer treatments that could potentially reach the clinic. Here, two new series of compounds are described: a family of antiangiogenic compounds, and a series of ICMT inhibitors that block Ras activity. These are two innovative examples of some of the most recent advances in the Medicinal Chemistry field, in the search for novel effective treatments for cancer. A must-read for anyone who wants to learn the first steps of drug development, as well as for any expert of the field who wants to stay current with the latest discoveries in the field of antitumor drugs.
Autorenporträt
Nagore Isabel Marín Ramos obtained her PharmD, PhD, and MBA in Spain with the highest distinction, winning the First National Award for Excellence in Academic Performance at University, and the First National Award in the Arquimedes Young Researchers Contest. She is currenlty working as a Postdoctoral Researcher at USC (Los Angeles).